Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor
- PMID: 21181476
- DOI: 10.1007/s00280-010-1513-8
Mechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor
Abstract
Gastrointestinal stromal tumor (GIST), the most common mesenchymal neoplasm of the GI tract and one of the most common sarcomas, is dependent on the expression of the mutated KIT or platelet-derived growth factor receptor in most cases. Imatinib mesylate potently abrogates the effects of KIT signaling by directly binding into the ATP-binding pocket of the kinase. It is becoming increasingly apparent that the binding affinity of imatinib for the receptor is dependent on the type and location of mutation. Within KIT, patients whose tumor has an exon 9 mutation are treated by many clinicians with higher doses of imatinib than those patients with mutations within exon 11. Additionally, there are over 400 unique mutations within exon 11 that may have distinctly different binding affinity for imatinib as well as other kinases. Secondary KIT mutations generally occur at a codon where imatinib binds resulting in KIT reactivation and resistance. Sunitinib malate, a second-generation KIT inhibitor is active in imatinib-resistant disease and is FDA-approved for use in this setting. In this review, we describe the biology of the genes and gene mutations responsible for GIST and discuss known and potential clinical implications.
Similar articles
-
[The importance of mutational status in prognosis and therapy of GIST].Recenti Prog Med. 2015 Jan;106(1):17-22. doi: 10.1701/1740.18950. Recenti Prog Med. 2015. PMID: 25621775 Italian.
-
The role of KIT in the management of patients with gastrointestinal stromal tumors.Hum Pathol. 2007 May;38(5):679-87. doi: 10.1016/j.humpath.2007.03.001. Hum Pathol. 2007. PMID: 17437861 Review.
-
[Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].Zhonghua Bing Li Xue Za Zhi. 2012 Jun;41(6):386-90. doi: 10.3760/cma.j.issn.0529-5807.2012.06.006. Zhonghua Bing Li Xue Za Zhi. 2012. PMID: 22932406 Chinese.
-
Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.J Clin Oncol. 2008 Nov 20;26(33):5352-9. doi: 10.1200/JCO.2007.15.7461. Epub 2008 Oct 27. J Clin Oncol. 2008. PMID: 18955458 Free PMC article. Clinical Trial.
-
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].Bull Cancer. 2008 Jan;95(1):107-16. doi: 10.1684/bdc.2008.0561. Bull Cancer. 2008. PMID: 18230576 Review. French.
Cited by
-
Autophagy is involved in endogenous and NVP-AUY922-induced KIT degradation in gastrointestinal stromal tumors.Autophagy. 2013 Feb 1;9(2):220-33. doi: 10.4161/auto.22802. Epub 2012 Nov 29. Autophagy. 2013. PMID: 23196876 Free PMC article.
-
A Rare Case of Breast Metastatic Gastrointestinal Stromal Tumor.Cureus. 2023 Jan 24;15(1):e34164. doi: 10.7759/cureus.34164. eCollection 2023 Jan. Cureus. 2023. PMID: 36843793 Free PMC article.
-
Progress in determining response to treatment in gastrointestinal stromal tumor.Expert Rev Anticancer Ther. 2020 Apr;20(4):279-288. doi: 10.1080/14737140.2020.1745068. Epub 2020 Apr 12. Expert Rev Anticancer Ther. 2020. PMID: 32191549 Free PMC article. Review.
-
Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials.Drug Des Devel Ther. 2014 Oct 30;8:2061-7. doi: 10.2147/DDDT.S63840. eCollection 2014. Drug Des Devel Ther. 2014. PMID: 25378911 Free PMC article.
-
What Is the Significance of Lysosomal-Mediated Resistance to Imatinib?Cells. 2023 Feb 23;12(5):709. doi: 10.3390/cells12050709. Cells. 2023. PMID: 36899844 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
